The FDA uncovered a second cancer-causing impurity in three batches of the blood pressure medicine valsartan. More: FDA finds more impurities in recalled high blood pressure drug valsartan Source: fierce
read moreDrug manufacturers were shaking off the remnants of Hurricane Florence today after the dangers from the “monstrous” storm morphed into dangerous flooding. More: Pfizer, Glaxo, Novo, Novartis plants unfazed by hurricane, resume production, Merck not as lucky Source: fierce
read moreAstraZeneca’s been struggling to measure up to archrival GlaxoSmithKline in the respiratory department, and the latest data on its triple-combination COPD candidate may not do much to help that situation. More: With latest data, can AstraZeneca's COPD triple combo rival
read moreThe race is on for a next-generation pneumococcal vaccine. Merck is already in phase 3 testing with its program, and Pfizer’s CFO said his company is “all in” on advancing its shot. More: Pfizer 'all in' on advancing next-generation pneumococcal
read moreWaiting for a key FDA decision in asthma due in about a month, Sanofi and Regeneron’s Dupixent has cut in with positive clinical results in adolescents with atopic dermatitis, an indication in which it’s currently approved for adults. More: Sanofi,
read moreIrish pharma Allergan is buying privately-held, clinical-stage US biotech Bonti for access to its novel, fast-acting neurotoxin programmes for aesthetic and therapeutic applications. More: Allergan snaps up Bonti Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals